Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AntiCov: Phase 3 comparison of SARS-CoV-2 neutralizing monoclonal antibodies versus standard of care in mild to moderate COVID-19
2021-004035-88Phase 3Completed
- Sponsor
- Policlinico Gemelli
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bamlanivimab, etesevimab, casirivimab, imdevimab and sotrovimab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Policlinico Gemelli. Started Aug 2021; status: completed.
02
Drugs
bamlanivimabetesevimabcasirivimabimdevimabsotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004035-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004035-88.